On July 15, 2026, Lakewood-Amedex Biotherapeutics Inc. released a corporate investor presentation detailing its Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials. The company highlighted its lead program, Nu-3, a topical antimicrobial gel for treating infected diabetic foot ulcers (iDFU), which has an open IND. Key upcoming milestones include the commencement of a clinical trial in 3Q26, with top-line results expected in 4Q26 or 1Q27. The company's intellectual property portfolio includes 101 patents with protection extending through 2044. The company is a clinical-stage biotechnology company developing antimicrobials to treat infectious diseases and combat antibiotic resistance.

On June 15, 2026, Lakewood-Amedex Biotherapeutics Inc. filed a Certificate of Change in Nevada to effectuate a 1-for-10 reverse stock split of its common stock. The split becomes effective at 4:01 p.m. ET on June 19, 2026, with split-adjusted trading on Nasdaq beginning June 22, 2026. This action reduces issued and outstanding shares from approximately 17,506,577 to 1,750,789 and reduces authorized shares to 12,500,000. Fractional shares will be rounded up to the next whole share. The company's ticker remains LABT, but a new CUSIP (51255A201) has been assigned. The company operates in the biotherapeutics industry, developing biological therapies.